Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 934-512-9 | CAS number: -
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Endpoint summary
Administrative data
Key value for chemical safety assessment
Genetic toxicity in vitro
Description of key information
Based on the study results, the test substance was considered to be non-mutagenic in the Ames test, with and without metabolic activation.
Link to relevant study records
- Endpoint:
- in vitro gene mutation study in bacteria
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Study period:
- From September 25, 2017 to October 23, 2017
- Reliability:
- 1 (reliable without restriction)
- Rationale for reliability incl. deficiencies:
- guideline study
- Qualifier:
- according to guideline
- Guideline:
- OECD Guideline 471 (Bacterial Reverse Mutation Assay)
- Deviations:
- no
- Qualifier:
- according to guideline
- Guideline:
- EU Method B.13/14 (Mutagenicity - Reverse Mutation Test Using Bacteria)
- Deviations:
- no
- Qualifier:
- according to guideline
- Guideline:
- EPA OPPTS 870.5100 - Bacterial Reverse Mutation Test (August 1998)
- Deviations:
- no
- Qualifier:
- according to guideline
- Guideline:
- JAPAN: Guidelines for Screening Mutagenicity Testing Of Chemicals
- Deviations:
- no
- GLP compliance:
- yes (incl. QA statement)
- Type of assay:
- bacterial reverse mutation assay
- Species / strain / cell type:
- S. typhimurium TA 1535, TA 1537, TA 98, TA 100 and E. coli WP2
- Additional strain / cell type characteristics:
- not specified
- Metabolic activation:
- with and without
- Metabolic activation system:
- Rat liver homogenate metabolizing system (10% liver S9 in standard co-factors)
- Test concentrations with justification for top dose:
- Experiment 1: 1.5, 5, 15, 50, 150, 500, 1500 and 5000 µg/plate (Presence and absence of S9)
Experiment 2: 1.5, 5, 15, 50, 150, 500, 1500 and 5000 µg/plate (Presence and absence of S9)
The maximum concentration was 5000 µg/plate (the maximum recommended dose level). - Vehicle / solvent:
- In solubility checks performed in–house, the test item was noted as insoluble sterile distilled water at 50 mg/mL but fully soluble in dimethyl sulphoxide at the same concentration. Dimethyl sulphoxide was selected as the vehicle.
- Untreated negative controls:
- yes
- Negative solvent / vehicle controls:
- yes
- Remarks:
- Identity: Dimethyl sulphoxide, Supplier: Fisher Scientific, Batch number (purity): 1710280 (>99%), Expiry: 06/2022
- Positive controls:
- yes
- Positive control substance:
- 4-nitroquinoline-N-oxide
- 9-aminoacridine
- N-ethyl-N-nitro-N-nitrosoguanidine
- benzo(a)pyrene
- other: Identity: 2-Aminoanthracene (2AA), CAS No.: 613-13-8, Batch number: STBB1901M9, Purity: 97.5%, Expiry date: 08 October 2019, Solvent: DMSO, Concentration: 1 µg/plate for TA100, 2 µg/plate for TA1535 and TA1537 , 10 µg/plate for WP2uvrA
- Details on test system and experimental conditions:
- Bacteria
The five strains of bacteria used, and their mutations, are as follows:
1) Salmonella typhimurium
Strains - Genotype - Type of mutations indicated
TA1537 - his C 3076; rfa-; uvrB-: - frame shift
TA98 - his D 3052; rfa-; uvrB-; - R-factor
TA1535 - his G 46; rfa-; uvrB-: - base-pair substitution
TA100 - his G 46; rfa-; uvrB-;R-factor
2) Escherichia coli
Strain - Genotype - Type of mutations indicated
WP2uvrA - trp-; uvrA-: - base-pair substitution
All of the Salmonella strains are histidine dependent by virtue of a mutation through the histidine operon and are derived from S. typhimurium strain LT2 through mutations in the histidine locus. Additionally due to the "deep rough" (rfa-) mutation they possess a faulty lipopolysaccharide coat to the bacterial cell surface thus increasing the cell permeability to larger molecules. A further mutation, through the deletion of the uvrB- bio gene, causes an inactivation of the excision repair system and a dependence on exogenous biotin. In the strains TA98 and TA100, the R factor plasmid pKM101 enhances chemical and UV-induced mutagenesis via an increase in the error prone repair pathway. The plasmid also confers ampicillin resistance which acts as a convenient marker (Mortelmans and Zeiger, 2000). In addition to a mutation in the tryptophan operon, the E. coli tester strain contains a uvrA- DNA repair deficiency which enhances its sensitivity to some mutagenic compounds. This deficiency allows the strain to show enhanced mutability as the uvrA repair system would normally act to remove and repair the damaged section of the DNA molecule (Green and Muriel, 1976 and Mortelmans and Riccio, 2000).
The bacteria used in the test were obtained from:
1) University of California, Berkeley, on culture discs, on 04 August 1995.
2) British Industrial Biological Research Association, on a nutrient agar plate, on 17 August 1987.
All of the strains were stored at approximately -196 °C in a Statebourne liquid nitrogen freezer, model SXR 34. In this assay, overnight sub-cultures of the appropriate coded stock cultures were prepared in nutrient broth (Oxoid Limited; lot number 1865318 05/21) and incubated at 37 °C for approximately 10 h. Each culture was monitored spectrophotometrically for turbidity with titres determined by viable count analysis on nutrient agar plates.
In this assay, overnight sub-cultures of the appropriate coded stock cultures were prepared in nutrient broth (Oxoid Limited; lot number 1865318 05/21) and incubated at 37°C for approximately 10 h. Each culture was monitored spectrophotometrically for turbidity with titres determined by viable count analysis on nutrient agar plates. - Evaluation criteria:
- There are several criteria for determining a positive result. Any, one, or all of the following can be used to determine the overall result of the study:
1) A dose-related increase in mutant frequency over the dose range tested (De Serres and Shelby, 1979).
2) A reproducible increase at one or more concentrations.
3) Biological relevance against in-house historical control ranges.
4) Statistical analysis of data as determined by UKEMS (Mahon et al., 1989).
5) Fold increase greater than two times the concurrent solvent control for any tester strain (especially if accompanied by an out of historical range response (Cariello and Piegorsch, 1996)).
A test substance will be considered non-mutagenic (negative) in the test system if the above criteria are not met.
Although most experiments will give clear positive or negative results, in some instances the data generated will prohibit making a definite judgment about test substance activity. Results of this type will be reported as equivocal. - Statistics:
- Statistical significance was confirmed by using Dunnetts Regression Analysis (* = p < 0.05) for those values that indicate statistically significant increases in the frequency of revertant colonies compared to the concurrent solvent control. Values that the program concluded as statistically significant but were within the in-house historical profile were not reported.
- Key result
- Species / strain:
- other: S. typhimurium TA 1535, TA 1537, TA 98, TA 100 and E. coli WP2 uvr A
- Metabolic activation:
- with and without
- Genotoxicity:
- negative
- Cytotoxicity / choice of top concentrations:
- no cytotoxicity nor precipitates, but tested up to recommended limit concentrations
- Vehicle controls validity:
- valid
- Untreated negative controls validity:
- valid
- Positive controls validity:
- valid
- Conclusions:
- Under the study conditions, the test substance was considered to be non-mutagenic in the Ames test, with and without metabolic activation.
- Executive summary:
A study was conducted to determine the genotoxic potential of the test substance, 'potassium lauroyl wheat amino acids' (active: 69.2%) using Ames test, according to OECD Guideline 471, EU Method B13/14 and the USA, EPA OCSPP harmonized guideline, in compliance with GLP. Salmonella typhimurium strains TA1535, TA1537, TA98 and TA100 and Escherichia coli strain WP2uvrA were treated with the test substance using both the Ames plate incorporation (Experiment 1) and pre-incubation (Experiment 2) methods at eight dose levels (i.e., 1.5, 5, 15, 50, 150, 500, 1500 and 5000 µg/plate), in triplicate, both with and without the addition of a rat liver homogenate metabolizing system (i.e., 10% liver S9 in standard co-factors). The dose range for Experiment 1 was predetermined and ranged from 1.5 to 5000 µg/plate. The experiment was repeated on a separate day using fresh cultures of the bacterial strains and fresh test substance formulations. Following the results of Experiment 1 (plate incorporation method), the dose range for Experiment 2 (pre-incubation method) was decided and kept the same (i.e., ranging from 1.5 to 5000 µg/plate), in order to achieve both four non‑toxic dose levels and the toxic limit of the test substance following the change in test methodology. The vehicle (dimethyl sulphoxide) control plates gave counts of revertant colonies generally within the normal range. All of the positive control chemicals used in the test induced marked increases in the frequency of revertant colonies, both with or without metabolic activation. Thus, the sensitivity of the assay and the efficacy of the S9 -mix were validated. The maximum dose level of the test substance in the first experiment was selected as the maximum recommended dose level of 5000 µg/plate. In Experiment 1/first mutation test (plate incorporation method) the test substance induced a toxic response, as weakened bacterial background lawns to all of the Salmonella strains in both the absence and presence of metabolic activation (S9 -mix) from 1500 µg/plate (TA100, TA1535 and TA1537) and at 5000 µg/plate (TA98). No toxicity was noted to Escherichia coli strain WP2uvrA. These results were not indicative of toxicity sufficiently severe enough to prevent the test substance being tested up to the maximum recommended dose level of 5000 µg/plate in the second mutation test/Experiment 2 (pre. Results from Experiment 2, showed that the test substance again induced a toxic response with weakened bacterial background lawns noted in the absence of S9 -mix from 150 µg/plate (TA1537), 500 µg/plate (TA100, TA1535 and TA98) and at 5000 µg/plate (WP2uvrA). In the presence S9 -mix weakened bacterial background lawns were noted from 500 µg/plate (TA100, TA1535 and TA1537), 1500 µg/plate (TA98) and at 5000 µg/plate (WP2uvrA). The sensitivity of the bacterial tester strains to the toxicity of the test substance varied slightly between strain type, exposures with or without S9 -mix and experimental methodology. A test substance precipitate (greasy in appearance) was noted from 5000 µg/plate, this observation did not prevent the scoring of revertant colonies. There were no biologically relevant increases in the frequency of revertant colonies recorded for any of the bacterial strains, with any dose of the test substance, either with or without metabolic activation (S9 -mix) in Experiment 1. Similarly, no biologically relevant increases in the frequency of revertant colonies were recorded for any of the bacterial strains, with any dose of the test substance, either with or without metabolic activation (S9 -mix) in Experiment 2. Statistically significant increases in TA1535 revertant colony frequency were observed in both the presence and absence of S9 -mix at 1500 µg/plate in Experiment 1. These increases were considered to have no biological relevance because weakened bacterial background lawns were also noted. Therefore the response would be due to additional histidine being available to His- bacteria allowing these cells to undergo several additional cell divisions and presenting as non-revertant colonies. A minor statistical value was also noted to TA1535 in Experiment 2 (presence of S9 -mix only) at 5 µg/plate, however the individual revertant counts were within the in-house historical vehicle/untreated control values for the strain and were, therefore considered of no biological relevance. Under the study conditions, the test substance was considered to be non-mutagenic in the Ames test, with and without metabolic activation (Envigo, 2017).
Reference
Results
Prior to use, the master strains were checked for characteristics, viability and spontaneous reversion rate (all were found to be satisfactory). The amino acid supplemented top agar and the S9-mix used in both experiments was shown to be sterile. The test substance formulation was also shown to be sterile. Results for the negative controls (spontaneous mutation rates) were considered to be acceptable. These data are for concurrent untreated control plates performed on the same day as the Mutation Test. The vehicle (dimethyl sulphoxide) control plates gave counts of revertant colonies generally within the normal range.A number of vehicle control counts for TA98 (dosed in the absence and presence of S9-mix after the first mutation test) were just above the historical control maxima. These counts were considered acceptable as they were within the expected control range outlined for the strain in the GSP, the untreated control counts were within expected range and the tester strain responded very well with the respective positive controls in both the presence and absence of S9‑mix.All of the positive control chemicals used in the test induced marked increases in the frequency of revertant colonies, both with or without metabolic activation. Thus, the sensitivity of the assay and the efficacy of the S9-mix were validated. The individual plate counts, the mean number of revertant colonies and the standard deviations, for the test substance, positive and vehicle controls, both with and without metabolic activation, are presented in Table 1 and Table 2 for Experiment 1 (plate incorporation) and Table 3 and Table 4 for Experiment 2 (pre-incubation).
Table
1:
Test Results: Experiment 1 – Without Metabolic Activation (Plate
Incorporation)
Test Period |
From: 06 October 2017 |
To: 09 October 2017 |
||||||||||
S9-Mix (-) |
Dose Level Per Plate |
Number of revertants (mean) +/- SD |
||||||||||
Base-pair substitution strains |
Frameshift strains |
|||||||||||
TA100 |
TA1535 |
WP2uvrA |
TA98 |
TA1537 |
||||||||
Solvent Control (DMSO) |
87 99 124 |
(103) 18.9# |
26 28 34 |
(29) 4.2 |
25 24 31 |
(27) 3.8 |
48 50 46 |
(48) 2.0 |
19 17 20 |
(19) 1.5 |
||
1.5 µg |
110 114 102 |
(109) 6.1 |
29 31 33 |
(31) 2.0 |
35 30 27 |
(31) 4.0 |
40 42 42 |
(41) 1.2 |
14 21 17 |
(17) 3.5 |
||
5 µg |
84 91 81 |
(85) 5.1 |
44 30 29 |
(34) 8.4 |
26 24 28 |
(26) 2.0 |
53 46 44 |
(48) 4.7 |
18 16 15 |
(16) 1.5 |
||
15 µg |
82 70 87 |
(80) 8.7 |
24 23 28 |
(25) 2.6 |
27 24 26 |
(26) 1.5 |
41 45 50 |
(45) 4.5 |
21 18 14 |
(18) 3.5 |
||
50 µg |
92 91 101 |
(95) 5.5 |
29 28 28 |
(28) 0.6 |
32 27 25 |
(28) 3.6 |
44 42 46 |
(44) 2.0 |
19 19 15 |
(18) 2.3 |
||
150 µg |
105 91 88 |
(95) 9.1 |
28 36 32 |
(32) 4.0 |
32 32 34 |
(33) 1.2 |
45 43 50 |
(46) 3.6 |
16 15 17 |
(16) 1.0 |
||
500 µg |
58 54 47 |
(53) 5.6 |
29 34 61 |
(41) 17.2 |
35 16 17 |
(23) 10.7 |
42 50 65 |
(52) 11.7 |
14 12 19 |
(15) 3.6 |
||
1500 µg |
56 S 45 S 43 S |
(48) 7.0 |
115 S 116 S 139 S |
*** (123) 13.6 |
32 27 29 |
(29) 2.5 |
33 32 38 |
(34) 3.2 |
8 S 6 S 4 S |
(6) 2.0 |
||
5000 µg |
0 VP 0 VP 0 VP |
(0) 0.0 |
0 VP 0 VP 0 VP |
(0) 0.0 |
18 P 20 P 22 P |
(20) 2.0 |
0 VP 0 VP 0 VP |
(0) 0.0 |
0 VP 0 VP 0 VP |
(0) 0.0 |
||
Positive controls S9-Mix (-) |
Name Dose Level No. of Revertants |
ENNG |
ENNG |
ENNG |
4NQO |
9AA |
||||||
3 µg |
5 µg |
2 µg |
0.2 µg |
80 µg |
||||||||
692 834 840 |
(789) 83.8 |
850 1188 1294 |
(1111) 231.9 |
984 1086 1100 |
(1057) 63.3 |
190 266 274 |
(243) 46.4 |
390 384 408 |
(394) 12.5 |
Table 2 : Test Results: Experiment 1 – With Metabolic Activation (Plate Incorporation)
Test Period |
From: 06 October 2017 |
To: 09 October 2017 |
||||||||||
S9-Mix (+) |
Dose Level Per Plate |
Number of revertants (mean) +/- SD |
||||||||||
Base-pair substitution strains |
Frameshift strains |
|||||||||||
TA100 |
TA1535 |
WP2uvrA |
TA98 |
TA1537 |
||||||||
Solvent Control (DMSO) |
93 77 88 |
(86) 8.2# |
38 33 37 |
(36) 2.6 |
32 34 39 |
(35) 3.6 |
57 52 53 |
(54) 2.6 |
22 17 19 |
(19) 2.5 |
||
1.5 µg |
91 85 99 |
(92) 7.0 |
30 25 31 |
(29) 3.2 |
32 48 36 |
(39) 8.3 |
60 53 61 |
(58) 4.4 |
19 19 20 |
(19) 0.6 |
||
5 µg |
91 91 89 |
(90) 1.2 |
43 27 31 |
(34) 8.3 |
31 37 34 |
(34) 3.0 |
63 55 55 |
(58) 4.6 |
21 17 20 |
(19) 2.1 |
||
15 µg |
80 87 82 |
(83) 3.6 |
28 30 28 |
(29) 1.2 |
32 36 33 |
(34) 2.1 |
59 58 64 |
(60) 3.2 |
15 18 18 |
(17) 1.7 |
||
50 µg |
82 92 96 |
(90) 7.2 |
37 30 36 |
(34) 3.8 |
30 38 34 |
(34) 4.0 |
55 63 60 |
(59) 4.0 |
18 21 22 |
(20) 2.1 |
||
150 µg |
87 86 83 |
(85) 2.1 |
36 39 37 |
(37) 1.5 |
35 37 27 |
(33) 5.3 |
67 42 54 |
(54) 12.5 |
15 20 21 |
(19) 3.2 |
||
500 µg |
84 93 93 |
(90) 5.2 |
32 29 31 |
(31) 1.5 |
34 31 33 |
(33) 1.5 |
69 63 50 |
(61) 9.7 |
23 26 18 |
(22) 4.0 |
||
1500 µg |
38 S 35 S 42 S |
(38) 3.5 |
170 S 200 S 152 S |
*** (174) 24.2 |
23 34 20 |
(26) 7.4 |
31 50 37 |
(39) 9.7 |
22 S 19 S 19 S |
(20) 1.7 |
||
5000 µg |
0 VP 0 VP 0 VP |
(0) 0.0 |
0 VP 0 VP 0 VP |
(0) 0.0 |
23 P 29 P 26 P |
(26) 3.0 |
0 VP 0 VP 0 VP |
(0) 0.0 |
0 TP 0 TP 0 TP |
(0) 0.0 |
||
Positive controls S9-Mix (+) |
Name Dose Level No. of Revertants |
2AA |
2AA |
2AA |
BP |
2AA |
||||||
1 µg |
2 µg |
10 µg |
5 µg |
2 µg |
||||||||
1520 1564 1752 |
(1612) 123.2 |
296 337 382 |
(338) 43.0 |
558 584 689 |
(610) 69.4 |
329 347 394 |
(357) 33.6 |
469 512 547 |
(509) 39.1 |
Table 3: Test Results: Experiment 2 – Without Metabolic Activation (Pre-Incubation)
Test Period |
From: 13 October 2017 19 October 2017† |
To: 16 October 2017 22 October 2017† |
||||||||||
S9-Mix (-) |
Dose Level Per Plate |
Number of revertants (mean) +/- SD |
||||||||||
Base-pair substitution strains |
Frameshift strains |
|||||||||||
TA100 |
TA1535 |
WP2uvrA |
TA98 |
TA1537† |
||||||||
Solvent Control (DMSO) |
92 104 126 |
(107) 17.2# |
14 16 14 |
(15) 1.2 |
38 39 23 |
(33) 9.0 |
11 22 19 |
(17) 5.7 |
21 15 17 |
(18) 3.1 |
||
1.5 µg |
122 117 101 |
(113) 11.0 |
15 16 13 |
(15) 1.5 |
28 29 15 |
(24) 7.8 |
25 20 9 |
(18) 8.2 |
17 17 14 |
(16) 1.7 |
||
5 µg |
113 115 86 |
(105) 16.2 |
16 13 16 |
(15) 1.7 |
30 29 31 |
(30) 1.0 |
25 17 16 |
(19) 4.9 |
13 18 19 |
(17) 3.2 |
||
15 µg |
118 119 110 |
(116) 4.9 |
14 12 11 |
(12) 1.5 |
26 17 29 |
(24) 6.2 |
22 21 24 |
(22) 1.5 |
11 9 15 |
(12) 3.1 |
||
50 µg |
89 110 101 |
(100) 10.5 |
18 14 18 |
(17) 2.3 |
31 32 26 |
(30) 3.2 |
26 21 17 |
(21) 4.5 |
19 19 24 |
(21) 2.9 |
||
150 µg |
106 109 125 |
(113) 10.2 |
12 8 15 |
(12) 3.5 |
29 37 15 |
(27) 11.1 |
15 18 18 |
(17) 1.7 |
6 S 4 S 11 S |
(7) 3.6 |
||
500 µg |
77 S 73 S 76 S |
(75) 2.1 |
8 S 8 S 16 S |
(11) 4.6 |
29 37 22 |
(29) 7.5 |
16 S 12 S 26 S |
(18) 7.2 |
3 S 4 S 4 S |
(4) 0.6 |
||
1500 µg |
0 V 0 V 0 V |
(0) 0.0 |
0 V 0 V 0 V |
(0) 0.0 |
28 24 16 |
(23) 6.1 |
0 V 0 V 0 V |
(0) 0.0 |
0 V 0 V 0 V |
(0) 0.0 |
||
5000 µg |
0 TP 0 TP 0 TP |
(0) 0.0 |
0 TP 0 TP 0 TP |
(0) 0.0 |
22 SP 15 SP 24 SP |
(20) 4.7 |
0 TP 0 TP 0 TP |
(0) 0.0 |
0 TP 0 TP 0 TP |
(0) 0.0 |
||
Positive controls S9-Mix (-) |
Name Dose Level No. of Revertants |
ENNG |
ENNG |
ENNG |
4NQO |
9AA |
||||||
3 µg |
5 µg |
2 µg |
0.2 µg |
80 µg |
||||||||
614 632 767 |
(671) 83.6 |
556 530 1299 |
(795) 436.7 |
765 722 795 |
(761) 36.7 |
216 212 203 |
(210) 6.7 |
230 178 226 |
(211) 28.9 |
Table 4: Test Results: Experiment 2 – With Metabolic Activation (Pre-Incubation)
Test Period |
From: 13 October 2017 |
To: 16 October 2017 |
||||||||||
S9-Mix (+) |
Dose Level Per Plate |
Number of revertants (mean) +/- SD |
||||||||||
Base-pair substitution strains |
Frameshift strains |
|||||||||||
TA100 |
TA1535 |
WP2uvrA |
TA98 |
TA1537 |
||||||||
Solvent Control (DMSO) |
107 102 129 |
(113) 14.4# |
12 8 13 |
(11) 2.6 |
34 38 35 |
(36) 2.1 |
28 37 28 |
(31) 5.2 |
23 14 15 |
(17) 4.9 |
||
1.5 µg |
102 114 88 |
(101) 13.0 |
11 14 5 |
(10) 4.6 |
42 37 31 |
(37) 5.5 |
30 32 24 |
(29) 4.2 |
16 19 19 |
(18) 1.7 |
||
5 µg |
107 95 124 |
(109) 14.6 |
26 18 21 |
* (22) 4.0 |
40 33 33 |
(35) 4.0 |
33 26 28 |
(29) 3.6 |
14 14 22 |
(17) 4.6 |
||
15 µg |
102 115 106 |
(108) 6.7 |
9 14 15 |
(13) 3.2 |
34 33 31 |
(33) 1.5 |
34 16 25 |
(25) 9.0 |
24 17 7 |
(16) 8.5 |
||
50 µg |
88 108 115 |
(104) 14.0 |
9 9 21 |
(13) 6.9 |
27 30 30 |
(29) 1.7 |
25 20 27 |
(24) 3.6 |
23 15 18 |
(19) 4.0 |
||
150 µg |
109 120 91 |
(107) 14.6 |
22 16 14 |
(17) 4.2 |
35 31 24 |
(30) 5.6 |
21 26 19 |
(22) 3.6 |
9 5 6 |
(7) 2.1 |
||
500 µg |
65 S 85 S 73 S |
(74) 10.1 |
12 S 7 S 10 S |
(10) 2.5 |
30 39 35 |
(35) 4.5 |
15 16 15 |
(15) 0.6 |
7 S 5 S 8 S |
(7) 1.5 |
||
1500 µg |
0 V 0 V 0 V |
(0) 0.0 |
0 V 0 V 0 V |
(0) 0.0 |
24 25 29 |
(26) 2.6 |
18 S 17 S 19 S |
(18) 1.0 |
0 V 0 V 0 V |
(0) 0.0 |
||
5000 µg |
0 TP 0 TP 0 TP |
(0) 0.0 |
0 TP 0 TP 0 TP |
(0) 0.0 |
22 SP 28 SP 17 SP |
(22) 5.5 |
0 VP 0 VP 0 VP |
(0) 0.0 |
0 TP 0 TP 0 TP |
(0) 0.0 |
||
Positive controls S9-Mix (+) |
Name Dose Level No. of Revertants |
2AA |
2AA |
2AA |
BP |
2AA |
||||||
1 µg |
2 µg |
10 µg |
5 µg |
2 µg |
||||||||
2287 1622 2234 |
(2048) 369.6 |
353 321 346 |
(340) 16.8 |
326 286 423 |
(345) 70.4 |
239 220 226 |
(228) 9.7 |
365 292 335 |
(331) 36.7 |
†: Experimental procedure repeated at a later date due to high colony counts in the original test
2AA: 2-Aminoanthracene
BP: Benzo(a)pyrene
ENNG: N-ethyl-N'-nitro-N-nitrosoguanidine
4NQO: 4-Nitroquinoline-1-oxide
9AA: 9-Aminoacridine
S: Sparse bacterial background lawn
T: Toxic, no bacterial background lawn
V: Very weak bacterial background lawn
#: Standard deviation
N/T: Not tested at this dose level
* p≤0.05
*** p≤0.001
The maximum dose level of the test substance in the first experiment was selected as the maximum recommended dose level of 5000 µg/plate. In the first mutation test (plate incorporation method) the test substance induced a toxic response as weakened bacterial background lawns to all of the Salmonella strains in both the absence and presence of metabolic activation (S9-mix) from 1500 µg/plate (TA100, TA1535 and TA1537) and at 5000 µg/plate (TA98). No toxicity was noted to Escherichia coli strain WP2uvrA. These results were not indicative of toxicity sufficiently severe enough to prevent the test substance being tested up to the maximum recommended dose level of 5000 µg/plate in the second mutation test. Results from Experiment 2 (pre-incubation method) showed that the test substance again induced a toxic response with weakened bacterial background lawns noted in the absence of S9 -mix from 150 µg/plate (TA1537), 500 µg/plate (TA100, TA1535 and TA98) and at 5000 µg/plate (WP2uvrA). In the presence S9 -mix weakened bacterial background lawns were noted from 500 µg/plate (TA100, TA1535 and TA1537), 1500 µg/plate (TA98) and at 5000 µg/plate (WP2uvrA). The sensitivity of the bacterial tester strains to the toxicity of the test substance varied slightly between strain type, exposures with or without S9 -mix and experimental methodology. A test substance precipitate (greasy in appearance) was noted from 5000 µg/plate, this observation did not prevent the scoring of revertant colonies. There were no biologically relevant increases in the frequency of revertant colonies recorded for any of the bacterial strains, with any dose of the test substance, either with or without metabolic activation (S9 -mix) in Experiment 1 (plate incorporation method). Similarly, no biologically relevant increases in the frequency of revertant colonies were recorded for any of the bacterial strains, with any dose of the test substance, either with or without metabolic activation (S9 -mix) in Experiment 2 (pre‑incubation method). Statistically significant increases in TA1535 revertant colony frequency were observed in both the presence and absence of S9 -mix at 1500 µg/plate in Experiment 1. These increases were considered to have no biological relevance because weakened bacterial background lawns were also noted. Therefore the response would be due to additional histidine being available to His- bacteria allowing these cells to undergo several additional cell divisions and presenting as non-revertant colonies. A minor statistical value was also noted to TA1535 in Experiment 2 (presence of S9 -mix only) at 5 µg/plate, however the individual revertant counts were within the in-house historical vehicle/untreated control values for the strain and were, therefore considered of no biological relevance. Under study conditions, the test substance was considered to be non-mutagenic with and without metabolic activation.
Endpoint conclusion
- Endpoint conclusion:
- no adverse effect observed (negative)
Genetic toxicity in vivo
Endpoint conclusion
- Endpoint conclusion:
- no study available
Additional information
A study was conducted to determine the genotoxic potential of the test substance, 'potassium lauroyl wheat amino acids' (active: 69.2%) using Ames test, according to the OECD Guideline 471, EU Method B13/14 and the USA, EPA OCSPP harmonized guideline, in compliance with GLP. Salmonella typhimurium strains TA1535, TA1537, TA98 and TA100 and Escherichia coli strain WP2uvrA were treated with the test substance using both the Ames plate incorporation (Experiment 1) and pre-incubation (Experiment 2) methods at eight dose levels (i.e., 1.5, 5, 15, 50, 150, 500, 1500 and 5000 µg/plate), in triplicate, both with and without the addition of a rat liver homogenate metabolizing system (i.e., 10% liver S9 in standard co-factors). The dose range for Experiment 1 was predetermined and ranged from 1.5 to 5000 µg/plate. The experiment was repeated on a separate day using fresh cultures of the bacterial strains and fresh test substance formulations. Following the results of Experiment 1 (plate incorporation method), the dose range for Experiment 2 (pre-incubation method) was kept the same (i.e., ranging from 1.5 to 5000 µg/plate), in order to achieve both four non‑toxic dose levels and the toxic limit of the test substance following the change in test methodology. The vehicle (dimethyl sulphoxide) control plates gave counts of revertant colonies generally within the normal range. All of the positive control chemicals used in the test induced marked increases in the frequency of revertant colonies, both with or without metabolic activation. Thus, the sensitivity of the assay and the efficacy of the S9 -mix were validated. The maximum dose level of the test substance in the first experiment was selected as the maximum recommended dose level of 5000 µg/plate. In Experiment 1/first mutation test (plate incorporation method) the test substance induced a toxic response as weakened bacterial background lawns to all of the Salmonella strains in both the absence and presence of metabolic activation (S9 -mix) from 1500 µg/plate (TA100, TA1535 and TA1537) and at 5000 µg/plate (TA98). No toxicity was noted to Escherichia coli strain WP2uvrA. These results were not indicative of toxicity sufficiently severe enough to prevent the test substance being tested up to the maximum recommended dose level of 5000 µg/plate in the second mutation test/Experiment 2 (pre. Results from Experiment 2, showed that the test substance again induced a toxic response with weakened bacterial background lawns noted in the absence of S9 -mix from 150 µg/plate (TA1537), 500 µg/plate (TA100, TA1535 and TA98) and at 5000 µg/plate (WP2uvrA). In the presence S9 -mix weakened bacterial background lawns were noted from 500 µg/plate (TA100, TA1535 and TA1537), 1500 µg/plate (TA98) and at 5000 µg/plate (WP2uvrA). The sensitivity of the bacterial tester strains to the toxicity of the test substance varied slightly between strain type, exposures with or without S9 -mix and experimental methodology. A test substance precipitate (greasy in appearance) was noted from 5000 µg/plate, this observation did not prevent the scoring of revertant colonies. There were no biologically relevant increases in the frequency of revertant colonies recorded for any of the bacterial strains, with any dose of the test substance, either with or without metabolic activation (S9 -mix) in Experiment 1. Similarly, no biologically relevant increases in the frequency of revertant colonies were recorded for any of the bacterial strains, with any dose of the test substance, either with or without metabolic activation (S9 -mix) in Experiment 2. Statistically significant increases in TA1535 revertant colony frequency were observed in both the presence and absence of S9 -mix at 1500 µg/plate in Experiment 1. These increases were considered to have no biological relevance because weakened bacterial background lawns were also noted. Therefore the response would be due to additional histidine being available to His- bacteria allowing these cells to undergo several additional cell divisions and presenting as non-revertant colonies. A minor statistical value was also noted to TA1535 in Experiment 2 (presence of S9 -mix only) at 5 µg/plate, however the individual revertant counts were within the in-house historical vehicle/untreated control values for the strain and were, therefore considered of no biological relevance. Under the study conditions, the test substance was considered to be non-mutagenic in the Ames test, with and without metabolic activation (Envigo, 2017).
Justification for classification or non-classification
Based on the absence of mutagenic response in an vitro Ames study, the test substance, 'potassium lauroyl wheat amino acids', does not warrant classification for genotoxicity, according to the EU CLP (Regulation 1272/2008/EC).
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.